最近，港交所生物制药上市企业“嘉和生物”向港交所递交上市申请书，揭开了港股首起18A未盈利生物科技公司反向并购案。反向并购，换句话说，也是借壳IPO，被视同为新上市申请，需要重新递交上市申请文件并接受审核。借壳方是一家红杉连续投资的B轮公司，亿腾医药。其通过换股方式反向收购嘉和生物，合并后亿腾医药股比将占较大比例，达到77.43%，而原嘉和生物股东将占较小比例，为22.57%。公司将更名为亿腾嘉和...
Source Link最近，港交所生物制药上市企业“嘉和生物”向港交所递交上市申请书，揭开了港股首起18A未盈利生物科技公司反向并购案。反向并购，换句话说，也是借壳IPO，被视同为新上市申请，需要重新递交上市申请文件并接受审核。借壳方是一家红杉连续投资的B轮公司，亿腾医药。其通过换股方式反向收购嘉和生物，合并后亿腾医药股比将占较大比例，达到77.43%，而原嘉和生物股东将占较小比例，为22.57%。公司将更名为亿腾嘉和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.